First Time Loading...

Entrada Therapeutics Inc
NASDAQ:TRDA

Watchlist Manager
Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc
NASDAQ:TRDA
Watchlist
Price: 14.17 USD -1.25% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

TRDA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Entrada Therapeutics, Inc. operates as a biotechnology company. [ Read More ]

The intrinsic value of one TRDA stock under the Base Case scenario is 6.6 USD. Compared to the current market price of 14.17 USD, Entrada Therapeutics Inc is Overvalued by 53%.

Key Points:
TRDA Intrinsic Value
Base Case
6.6 USD
Overvaluation 53%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Entrada Therapeutics Inc

Backtest TRDA Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TRDA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
Entrada Therapeutics Inc

Current Assets 369.8m
Cash & Short-Term Investments 352m
Receivables 5.9m
Other Current Assets 11.9m
Non-Current Assets 99.4m
PP&E 92.7m
Other Non-Current Assets 6.7m
Current Liabilities 158.8m
Accounts Payable 3.3m
Accrued Liabilities 19.2m
Other Current Liabilities 136.3m
Non-Current Liabilities 68m
Other Non-Current Liabilities 68m
Efficiency

Earnings Waterfall
Entrada Therapeutics Inc

Revenue
129m USD
Operating Expenses
-132.2m USD
Operating Income
-3.2m USD
Other Expenses
-3.5m USD
Net Income
-6.7m USD

Free Cash Flow Analysis
Entrada Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

TRDA Profitability Score
Profitability Due Diligence

Entrada Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Entrada Therapeutics Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

TRDA Solvency Score
Solvency Due Diligence

Entrada Therapeutics Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
55/100
Solvency
Score

Entrada Therapeutics Inc's solvency score is 55/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TRDA Price Targets Summary
Entrada Therapeutics Inc

Wall Street analysts forecast TRDA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TRDA is 21.42 USD with a low forecast of 20.2 USD and a high forecast of 23.1 USD.

Lowest
Price Target
20.2 USD
43% Upside
Average
Price Target
21.42 USD
51% Upside
Highest
Price Target
23.1 USD
63% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TRDA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TRDA Price
Entrada Therapeutics Inc

1M 1M
+7%
6M 6M
-10%
1Y 1Y
-4%
3Y 3Y
-29%
5Y 5Y
-29%
10Y 10Y
-29%
Annual Price Range
14.17
52w Low
11.02
52w High
18.01
Price Metrics
Average Annual Return -17.98%
Standard Deviation of Annual Returns 3.72%
Max Drawdown -84%
Shares Statistics
Market Capitalization 473.8m USD
Shares Outstanding 33 368 100
Percentage of Shares Shorted 9.38%

TRDA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Entrada Therapeutics Inc Logo
Entrada Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

473.8m USD

Dividend Yield

0%

Description

Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.

Contact

MASSACHUSETTS
Boston
6 Tide Street
+18573051825.0
https://www.entradatx.com/

IPO

2021-10-29

Employees

114

Officers

CEO & Director
Mr. Dipal Doshi
President & COO
Mr. Nathan J. Dowden
Chief Scientific Officer
Dr. Natarajan Sethuraman Ph.D.
CFO & Treasurer
Mr. Kory James Wentworth CPA
General Counsel
Dr. Jared Cohen J.D., Ph.D.
Senior Vice President of People
Ms. Kerry Robert M.S.
Show More
Chief Corporate Affairs Officer
Ms. Karla MacDonald
Show Less

See Also

Discover More
What is the Intrinsic Value of one TRDA stock?

The intrinsic value of one TRDA stock under the Base Case scenario is 6.6 USD.

Is TRDA stock undervalued or overvalued?

Compared to the current market price of 14.17 USD, Entrada Therapeutics Inc is Overvalued by 53%.